On June 18, 2025, Agios Pharmaceuticals' stockholders approved a plan to increase the shares available for its stock incentive plan by 2.5 million and elected two directors for three-year terms. They also ratified PricewaterhouseCoopers as the accounting firm and approved executive compensation with notable votes for and against each proposal.